Literature DB >> 18852924

Risk-profile and outcome of small papillary and follicular thyroid carcinomas (<or=1 cm).

K Rahbar1, V Hutzenlaub, R-J Fischer, O Schober, B Riemann.   

Abstract

AIM: According to the procedure guidelines of the German Society of Nuclear Medicine no radioiodine ablation is necessary in patients with papillary microcarcinomas in case of limited surgical resection. Few data are available with respect to the optimal management of patients with small follicular thyroid carcinomas. It was the aim to compare risk-profile and outcome of patients with small papillary (PTC) and follicular thyroid carcinomas (FTC) <or=1 cm. PATIENTS,
METHODS: 1594 patients with thyroid cancer were attended at our department between 1995 and 2006. For the subgroup of 383 patients with small PTC and FTC <or=1 cm a comparative correlation of multifocality, extrathyroidal growth, lymph node spread, distant metastasis, local recurrence and survival was performed. Patients were monitored for a mean follow-up time of six years.
RESULTS: A total of 361 patients had PTC and 22 FTC <or=1 cm. At presentation the mean age of the 306 women and 77 men was 49 +/- 13 years. An ablative radioiodine therapy was performed in 77% and 100% of patients with small PTC and FTC, respectively. Multifocality (14% vs. 9%), extrathyroidal growth (10% vs. 5%), lymph node spread (14% vs. 5%), local recurrence (0.5% vs. 0%) and progressive disease (1% vs. 0%) were more common in patients with small PTC than FTC, whereas the corresponding values for distant metastasis were 2% vs. 5%, respectively; however, these figures did not reach statistical significance. Eight patients with papillary microcarcinomas died because of nonthyroidal diseases.
CONCLUSION: Our data show no statistically significant differences in the risk-profile and outcome of patients with small PTC and FTC <or=1 cm. Therefore, the decision for or against radioiodine ablation in patients with small differentiated thyroid carcinomas should be discussed individually.

Entities:  

Mesh:

Year:  2008        PMID: 18852924     DOI: 10.3413/nukmed-0147

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  3 in total

Review 1.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

2.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

3.  Follicular thyroid cancer incidence patterns in the United States, 1980-2009.

Authors:  Briseis Aschebrook-Kilfoy; Raymon H Grogan; Mary H Ward; Edwin Kaplan; Susan S Devesa
Journal:  Thyroid       Date:  2013-07-20       Impact factor: 6.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.